The Hidden Language of Metabolism.
Insulin is one of the most underutilized signal in medicine. Our sensing technology transforms metabolic health from reactive treatment to proactive mastery.
Hyperinsulinemia
The silent driver
THE CHALLENGE
Most Metabolic Disease Begins With a Single, Silent Signal.
Obesity, diabetes, cardiovascular disease, and neurodegeneration share a common root: insulin dysregulation. Yet this critical biomarker remains invisible in routine care—detected only after damage has occurred.
THE SOLUTION
Why Insulin Matters
Beyond glucose control, insulin orchestrates cellular aging, inflammation, cognitive function, and vascular health. Hyperinsulinemia precedes visible disease by years—or decades.
Predictive Window
Elevated insulin appears 10-15 years before glucose abnormalities, offering a critical intervention window.
50%+ Prevalence
More than half of adults have some degree of insulin resistance—most without any symptoms or awareness.
Actionable Data
Real-time insulin monitoring enables precise dietary, lifestyle, and therapeutic interventions tailored to individual response.
CLINICAL APPLICATIONS
Cross-Specialty Utility
Insulin dysregulation underlies disease across cardiology, endocrinology, neurology, and reproductive medicine. Select a condition to explore the evidence.
Colorectal Cancer
Colorectal Cancer
Evidence of association
Elevated fasting insulin: 1.5-2-fold higher CRC risk independent of glucose/BMI. Japan Public Health Center study: fasting C-peptide and HOMA-IR predicted CRC over 15 years. Higher adenomatous polyp recurrence in MetS/hyperinsulinemia.
Mechanistic pathway
Insulin/IGF-1 stimulate colonic epithelial proliferation and inhibit apoptosis via PI3K/Akt/mTOR and MAPK/ERK. Suppressed IGFBP-1/2 increases free IGF-1, activating β-catenin/Wnt pathway. COX-2/PGE2 upregulation and dysbiosis contribute.
Clinical implication
Metformin lowers polyp recurrence and improves survival. Exercise and dietary fiber correlate with improved prognosis. Combination metabolic-inflammatory therapies under investigation.
Endometrial Cancer
Endometrial Cancer
Evidence of association
Highest fasting insulin/HOMA-IR quartile: 2-3-fold higher endometrial cancer risk. 2024 meta-analysis: pooled RR 1.89 for IR, 2.21 for hyperinsulinemia.
Mechanistic pathway
Insulin/IGF-1 directly stimulate endometrial proliferation via PI3K/Akt and MAPK. Hyperinsulinemia suppresses SHBG, increasing bioavailable estrogens. High leptin/low adiponectin creates tumor-permissive oxidative stress and angiogenesis.
Clinical implication
Metformin and TZDs show antiproliferative effects (AMPK activation, mTOR inhibition). Routine metabolic screening (HOMA-IR, TyG) should be integrated into gynecologic cancer risk assessment.
Breast Cancer
Breast Cancer
Evidence of association
Highest fasting insulin quartile: 2-3-fold higher breast cancer risk in postmenopausal women. 2025 meta-analysis (100,000+ participants): hyperinsulinemia RR 1.54. Insulin/C-peptide correlate with recurrence and mortality.
Mechanistic pathway
Insulin activates INSR/IGF-1R, stimulating PI3K/Akt/mTOR and MAPK pathways that upregulate cyclin D1 and suppress pro-apoptotic proteins. Hyperinsulinemia increases hepatic IGF-1 and enhances adipose aromatase activity (local estrogen production).
Clinical implication
Metformin shows potential as adjuvant, reducing recurrence in IR patients. Lifestyle interventions (caloric restriction, low-glycemic diet, exercise) reduce insulin and leptin levels.
Pancreatic Cancer
Pancreatic Cancer
Evidence of association
2024 meta-analysis (2M+ subjects): RR 1.87 for PDAC in diabetics, 1.62 in IR non-diabetics. Mendelian randomization confirms causal relationship between elevated fasting insulin and PDAC (glucose shows no independent effect).
Mechanistic pathway
Hyperinsulinemia activates insulin/IGF-1R signaling (PI3K/Akt/mTOR, MAPK), synergizing with KRAS mutations present in >90% of PDAC. NF-κB/JNK activation induces acinar-to-ductal metaplasia. Insulin enhances stellate cell activation and VEGF-mediated angiogenesis.
Clinical implication
Metformin associated with reduced PDAC risk and improved survival (AMPK activation, mTOR inhibition). Lifestyle modification decreases fasting insulin and inflammatory tone.
Depression & Anxiety
Depression & Anxiety
Evidence of association
NESDA study (n=2,590): higher fasting insulin and lower QUICKI associated with greater depression severity/chronicity. Meta-analysis (20,000+ subjects): IR increases depression odds by ~60%.
Mechanistic pathway
Insulin modulates dopamine/serotonin synthesis, hippocampal neurogenesis, and neuroplasticity. IR diminishes neuronal glucose uptake, impairs mesolimbic dopamine transmission, and heightens inflammatory cytokines. HPA axis activation links metabolic dysfunction to stress reactivity.
Clinical implication
Metformin, pioglitazone, and GLP-1 analogs show antidepressant effects. IR predicts reduced SSRI/SNRI response - metabolic screening may inform personalized treatment.
Alzheimer's Disease
Alzheimer's Disease
Evidence of association
Brain insulin resistance is a hallmark of AD. Postmortem studies show reduced insulin receptor density and impaired phosphorylation in hippocampus/cortex. T2DM and hyperinsulinemia increase AD risk 2-3-fold.
Mechanistic pathway
Defective brain insulin signaling impairs PI3K-Akt-GSK3β, causing tau hyperphosphorylation and neurofibrillary tangles. Excess insulin competes with β-amyloid for insulin-degrading enzyme, accelerating amyloid accumulation.
Clinical implication
Brain IR is potentially reversible early. Intranasal insulin improves working memory without systemic hypoglycemia. GLP-1 agonists and PPAR-γ modulators show neuroprotective potential.
market opportunity
Insulin Is Moving Upstream in Clinical Care
The role of insulin is expanding beyond diabetes.
Clinical evidence shows it is a critical biomarker in time-sensitive conditions and an early indicator of metabolic risk — long before glucose and HbA1c become abnormal.
40M+
Test / year
Across chronic metabolic conditions where insulin adds early clinical insight.
150M+
PEOPLE
People globally affected by insulin-driven metabolic dysfunction across women’s health, obesity, and early cardiometabolic risk.
10+
year
Earlier metabolic insight vs glucose-based diagnostics.
team
Join us
We’re building Hybolic to solve one of the hardest problems in metabolic health. This requires exceptional people. If you’re excited about what we’re creating but don’t see a matching role, send us your CV through the Open Application form.
Early team, real ownership
As part of a small founding team, your work will directly shape the product, technology, and company.
Build breakthrough technology
Work at the intersection of science, engineering, and deep-tech innovation.
Move fast, learn faster
We value curiosity, initiative, and people who want to grow while solving hard problems.
Request Access
Join our growing waitlist of people and our team will keep you updated.